CTOs on the Move

Intra-Cellular Therapies

www.intracellulartherapies.com

 
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Remedi

Remedi SeniorCare is a United States-based institutional pharmacy business, serving a growing number of facilities extending from the Mid-Atlantic to the Midwest.

BCY LifeSciences

BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SubjectWell

SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize.

Allstar Genetics

Allstar Genetics is a Celina, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.